Harpoon Therapeutics, Inc. is now a wholly-owned subsidiary of Merck. Together we’ll work to advance important innovations to help address the needs of people with #cancer worldwide. Follow @Merck for all future updates and learn more: merck.com/news/merck-complet…
Read more about our recent news in our press release here: ir.harpoontx.com/news-releas…
8
2
186
$HARP is pleased to announce the promotion of Wendy Chang to Chief People Officer. Ms. Chang joined in 2022 as SVP of HR and she brings more than 20 years of experience to the role.
View our PR: ir.harpoontx.com/news-releas…
#immunooncology #TCell #cancer #HPN217 #biotech
2
2
240
$HARP to present updated interim results from the Phase 1/2 clinical trial of T Cell engager #HPN328 at American Society of Clinical Oncology (@ASCO) - Genitourinary Cancers
View full release here: ir.harpoontx.com/news-releas…
#immunooncology #TCell #cancer #biotech #ASCOGU2024
419
Today $HARP presented results from the completed Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma at #ASH23 and declared 12 mg #RP2D
View release: ir.harpoontx.com/news-releas…
#immunooncology #TCell #cancer #biotech #ASH2023
1
128
Now available: our third quarter 2023 financial results. Learn more about the results and highlights here: ir.harpoontx.com/news-releas…
$HARP #immunooncology #TCell #cancer #HPN217 #HPN328 #biotech #earnings #financialresults
2
347
$HARP announced upcoming oral presentation of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma at #ASH2023
View full release here: ir.harpoontx.com/news-releas…
#immunooncology #TCell #cancer #biotech @ASH_hematology
5
348
$HARP announced that it has entered into a securities purchase agreement for a #PIPE of up to $150M, led by leading #biotechnology investors
View release: ir.harpoontx.com/news-releas…
Post-ESMO webcast replay available: icr.swoogo.com/Harpoontx?i=W…
#TCell #cancer #ESMO2023 #financing
$HARP announced updated interim monotherapy data from its Phase 1/2 trial for HPN328 in #SCLC and other #neuroendocrine tumor types at @myESMO
View release: ir.harpoontx.com/news-releas…
Post-ESMO webcast: icr.swoogo.com/Harpoontx?i=W…
#immunooncology #TCell #biotech #cancer #ESMO2023
3
583
Join $HARP for a live webcast reviewing interim monotherapy data from its Phase 1/2 clinical trial evaluating #HPN328 in #SCLC and #NEN presented at @myESMO
Registration is open now: icr.swoogo.com/Harpoontx?i=W…
View release: ir.harpoontx.com/news-releas…
#TCell #cancer #ESMO2023
3
599
Harpoon to present interim tolerability and response data from the Phase 1/2 clinical trial of T Cell engager #HPN328 at @myESMO
View full release here: ir.harpoontx.com/news-releas…
$HARP #immunooncology #TCell #cancer #biotech #ESMO23
3
465
Today at #IMS23, we shared interim Phase 1 data for HPN217 in relapsed / refractory multiple myeloma.
View full release here: ir.harpoontx.com/news-releas…
$HARP #immunooncology #TCell #cancer #biotech
1
95
Today we announced the dosing of the first patients with #SCLC in an ongoing Phase 1/2 trial of #HPN328 in a combination cohort
Learn more here: ir.harpoontx.com/news-releas…
Join us at 8:00 a.m. ET for our DLL3 KOL event: protect-us.mimecast.com/s/Ml…
$HARP
1
76
Join $HARP on Sept 15 at 8:00 a.m. ET for a KOL discussion of #DLL3 and #HPN328 featuring two leading #oncologists Himisha Beltran, M.D. and Erin Schenk, M.D., Ph.D.
Learn more: ir.harpoontx.com/news-releas…
Register now: viavid.webcasts.com/starther…
#immunooncology #TCell #cancer
1
70
Join $HARP for a fireside chat at the @HCWCO Conference on Sept 11th at 3:30 p.m. ET and at @Citi’s 18th Annual BioPharma Conference on Sept 7th.
Webcast: ir.harpoontx.com/events-and-…
#immunooncology #TCell #cancer #HPN217 #HPN328 #biotech
ir.harpoontx.com/news-releas…
1
58
Now available: our second quarter 2023 financial results. Learn more about the results and highlights here: ir.harpoontx.com/news-releas…
$HARP #immunooncology #TCell #cancer #HPN217 #HPN328 #biotech #earnings #financialresults
1
112
Join $HARP at the @CG_Driven Annual Growth Conference and at the @HCWCO Immune Cell Engager Virtual Conference
Webcasts will be available on Harpoon’s website: ir.harpoontx.com/events-and-…
$HARP #immunooncology #TCell #cancer #HPN217 #HPN328 #biotech
1
106
We are pleased to welcome Haibo Wang as SVP of Business Development. Mr. Wang brings us 15 years of experience in #biopharma business development, finance, and M&A, including deep experience in #Tcell engagers.
View our release: ir.harpoontx.com/news-releas…
$HARP #immunooncology
1
72




















